Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2504-2519
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2504
Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy
Di Pan, Hao-Nan Liu, Zhi-Yuan Yao, Xiao-Xiao Chen, Yu-Qi Li, Jing-Jing Zhu, Zheng-Xiang Han, Xiao-Bing Qin
Di Pan, Hao-Nan Liu, Zhi-Yuan Yao, Xiao-Xiao Chen, Yu-Qi Li, Jing-Jing Zhu, Zheng-Xiang Han, Xiao-Bing Qin, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China
Co-first authors: Di Pan and Hao-Nan Liu.
Co-corresponding authors: Zheng-Xiang Han and Xiao-Bing Qin.
Author contributions: Qin XB and Han ZX designed the study; Pan D, Liu HN and Yao ZY collected the clinical data; Chen XX, Li YQ and Zhu JJ analyzed the data; Pan D, Liu HN and Yao ZY wrote the paper; Qin XB and Han ZX revised the paper; all authors contributed to the article and approved the submitted version. There are several reasons for designating Pan D and Liu HN as co-first authors, Qin XB and Han ZX as co-corresponding authors. Firstly, this study is a collaborative study, the setting of co-first authors and co-corresponding authors accurately reflects the distribution of responsibilities and burdens related to the time, effort required to complete the study and the final paper. This also ensures effective communication and management of post submission matters, ultimately improving the quality and reliability of the paper. Secondly, the completion of this study requires research design, conceptualization, and implementation (including data collection, data processing, and chart making), which require authors with different professional knowledge and skills. The designation of co-first authors and co-corresponding authors best reflects this diversity. Most importantly, Pan D and Liu HN made equally substantial efforts throughout the entire research process. Choose these researchers as co-first authors, acknowledge and respect this equal contribution, while recognizing the team spirit and collaborative spirit of this study. Qin XB and Han ZX developed detailed ideas for this study, reviewed the specific implementation process, supervised the overall quality and reliability of the paper. In summary, we believe that designating Pan D and Liu HN as co- first authors, Qin XB and Han ZX as co-corresponding authors, is suitable for our manuscript as it accurately reflects the collaborative spirit, equal contribution, and diversity of our team.
Institutional review board statement: The studies involving human participants were reviewed and approved by the Ethics Committee of Clinical Trials (Approval No. XYFY2022-KL207-01).
Informed consent statement: Due to the retrospective nature of this study, we waived the requirement for written informed consent.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at qin_xiaobing@163.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Bing Qin, MD, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 West Huaihai Road, Quanshan District, Xuzhou 221000, Jiangsu Province, China. qin_xiaobing@163.com
Received: February 18, 2024
Revised: April 21, 2024
Accepted: April 26, 2024
Published online: June 15, 2024
Processing time: 117 Days and 11.9 Hours
Core Tip

Core Tip: In this manuscript, we revisited the different clinical outcomes of hepatocellular carcinoma (HCC) patients treated with camrelizumab in combination with lenvatinib, explored the different clinical outcomes of HCC patients with different baseline hepatitis B virus viral load, and developed a predictive model with nomograms based on the results of COX regression.